Mechanistic characterization of SARS-CoV2 associated kidney injury

SARS-CoV2相关肾损伤的机制特征

基本信息

  • 批准号:
    10427448
  • 负责人:
  • 金额:
    $ 39.38万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-06-11 至 2024-04-30
  • 项目状态:
    已结题

项目摘要

SARS-CoV2 is a highly contagious, novel human coronavirus that causes coronavirus disease 2019 (COVID- 19). Currently over 16.5 million people in the US have confirmed infection with SARS-CoV2 and over 300,000 have died. Severe COVID-19 is characterized by pulmonary and systemic inflammation and multi-organ dysfunction, with a significant portion of severe COVID patients developing acute kidney injury. The mechanism by which SARS-CoV2 triggers such severe pathogenesis is poorly understood. Recent clinical studies have suggested that cell death, especially the induction of necroptosis, may be a predictor of severe COVID-19 disease. The mechanism by which the host restricts necroptosis is unclear. In preliminary data we have shown that the interferon induced protein, ISG15, acts as a negative regulator of necroptosis and its downstream inflammatory responses during viral infection. We have also shown that ISG15 deficient mice rapidly succumb to ischemia-reperfusion injury of the kidney characterized by a massive release of proinflammatory cytokines. In this proposal we will test the hypothesis that ISG15 serves as a critical host restriction factor in regulating programmed necroptosis and downstream inflammatory responses within the kidney to limit acute kidney injury during SARS-CoV2 infection. We will utilize kidney organoids derived from induce pluripotent stem cells in which ISG15 has been deleted by CRISPR, a co-culture system with kidney organoids and primary tracheal epithelial cultures (hTECs), and in vivo mouse model of SARS-CoV-2 to ask several questions including: 1) Does SARS- CoV2 induce damage to kidney epithelial cells via direct viral transduction or in response to systemic inflammation?; 2) Does ISG15 modulate necroptotic cell death as well as proinflammatory cytokine/chemokine production in kidney epithelial cells during SARS-CoV2 infection?; 3) Does necroptosis and its regulation by ISG15 contribute to acute kidney injury during SARS-CoV2 infection? Overall, our studies will provide important insight into host factors that restrict necroptosis and could be an important contributor to severe COVID-19 induced kidney injury.
SARS-CoV2 是一种高度传染性的新型人类冠状病毒,可导致 2019 年冠状病毒病 (COVID-19) 19)。目前美国已有超过 1650 万人确诊感染 SARS-CoV2,超过 30 万人 已经死了。严重的 COVID-19 的特点是肺部和全身炎症以及多器官 功能障碍,相当一部分重症新冠患者出现急性肾损伤。机制 SARS-CoV2 是如何引发如此严重的发病机制的,目前人们知之甚少。最近的临床研究已 表明细胞死亡,尤其是坏死性凋亡的诱导,可能是严重 COVID-19 的预测因素 疾病。宿主限制坏死性凋亡的机制尚不清楚。在初步数据中我们已经显示 干扰素诱导蛋白 ISG15 充当坏死性凋亡及其下游的负调节因子 病毒感染期间的炎症反应。我们还表明,ISG15 缺陷小鼠会迅速死亡 以大量释放促炎细胞因子为特征的肾脏缺血再灌注损伤。 在本提案中,我们将测试 ISG15 在调节中作为关键宿主限制因素的假设 肾脏内的程序性坏死性凋亡和下游炎症反应,以限制急性肾损伤 SARS-CoV2 感染期间。我们将利用源自诱导多能干细胞的肾脏类器官,其中 ISG15 已被 CRISPR 删除,这是一种与肾类器官和原代气管上皮共培养系统 培养物(hTEC)和 SARS-CoV-2 体内小鼠模型,提出几个问题,包括:1)SARS- 冠状病毒2通过直接病毒转导或响应全身性诱导肾上皮细胞损伤 炎?; 2) ISG15是否调节坏死性细胞死亡以及促炎细胞因子/趋化因子 SARS-CoV2 感染期间肾上皮细胞的产生? 3) 程序性坏死及其调控 ISG15 会导致 SARS-CoV2 感染期间的急性肾损伤吗?总的来说,我们的研究将提供重要的 深入了解限制坏死性凋亡的宿主因素,并可能是导致严重 COVID-19 的重要因素 诱发肾损伤。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Deborah J Lenschow其他文献

Deborah J Lenschow的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Deborah J Lenschow', 18)}}的其他基金

Mechanistic characterization of SARS-CoV2 associated kidney injury
SARS-CoV2相关肾损伤的机制特征
  • 批准号:
    10319713
  • 财政年份:
    2021
  • 资助金额:
    $ 39.38万
  • 项目类别:
Regulation of Cell Death and Inflammation by ISG15 during SARS-CoV2 Infection
SARS-CoV2 感染期间 ISG15 对细胞死亡和炎症的调节
  • 批准号:
    10287787
  • 财政年份:
    2021
  • 资助金额:
    $ 39.38万
  • 项目类别:
Regulation of Cell Death and Inflammation by ISG15 during SARS-CoV2 Infection
SARS-CoV2 感染期间 ISG15 对细胞死亡和炎症的调节
  • 批准号:
    10424558
  • 财政年份:
    2021
  • 资助金额:
    $ 39.38万
  • 项目类别:
Mechanistic characterization of SARS-CoV2 associated kidney injury
SARS-CoV2相关肾损伤的机制特征
  • 批准号:
    10619568
  • 财政年份:
    2021
  • 资助金额:
    $ 39.38万
  • 项目类别:
Washington University Rheumatic DiseasesResearch Resource-based Center
华盛顿大学风湿病研究资源中心
  • 批准号:
    10472003
  • 财政年份:
    2018
  • 资助金额:
    $ 39.38万
  • 项目类别:
Washington University Rheumatic Diseases Research Resource-based Center
华盛顿大学风湿病研究资源中心
  • 批准号:
    10704273
  • 财政年份:
    2018
  • 资助金额:
    $ 39.38万
  • 项目类别:
Washington University Rheumatic DiseasesResearch Resource-based Center
华盛顿大学风湿病研究资源中心
  • 批准号:
    9764270
  • 财政年份:
    2018
  • 资助金额:
    $ 39.38万
  • 项目类别:
Washington University Rheumatic DiseasesResearch Resource-based Center
华盛顿大学风湿病研究资源中心
  • 批准号:
    10019327
  • 财政年份:
    2018
  • 资助金额:
    $ 39.38万
  • 项目类别:
Washington University Rheumatic DiseasesResearch Resource-based Center
华盛顿大学风湿病研究资源中心
  • 批准号:
    10251236
  • 财政年份:
    2018
  • 资助金额:
    $ 39.38万
  • 项目类别:
REGULATION OF INFLUENZA VIRUS INFECTION BY ISG15
ISG15 对流感病毒感染的监管
  • 批准号:
    8109260
  • 财政年份:
    2009
  • 资助金额:
    $ 39.38万
  • 项目类别:

相似国自然基金

巨噬细胞Nogo-B通过FABP4/IL-18/IL-18R调控急性肝衰竭的分子机制研究
  • 批准号:
    82304503
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
基于解郁散热“把好气分关”探讨代谢-炎症“开关”A2BR在急性胰腺炎既病防变中的作用与机制
  • 批准号:
    82374256
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目
RacGAP1介导细胞核-线粒体对话在急性肾损伤中促进肾小管上皮细胞能量平衡的作用机制研究
  • 批准号:
    82300771
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
开窍寒温配伍调控应激颗粒铁离子富集水平抗急性缺血性卒中铁死亡损伤的机制研究
  • 批准号:
    82374209
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目

相似海外基金

Covid-19 induced worsening of glomerular diseases
Covid-19 导致肾小球疾病恶化
  • 批准号:
    10655140
  • 财政年份:
    2023
  • 资助金额:
    $ 39.38万
  • 项目类别:
Phenotyping ARDS, Pneumonia, and Sepsis over time to elucidate shared and distinct trajectories ofillness and recovery
随着时间的推移对 ARDS、肺炎和脓毒症进行表型分析,以阐明共同和不同的疾病和康复轨迹
  • 批准号:
    10649194
  • 财政年份:
    2023
  • 资助金额:
    $ 39.38万
  • 项目类别:
COVID-19 and Kidney Injury: Urinary Transcriptomics of Kidney Injury in Novel Nonhuman Primate Models of SARS-CoV-2
COVID-19 和肾损伤:SARS-CoV-2 新型非人灵长类动物模型中肾损伤的尿转录组学
  • 批准号:
    10453220
  • 财政年份:
    2022
  • 资助金额:
    $ 39.38万
  • 项目类别:
A new therapeutic approach against kidney damage in LN and COVID-19
针对 LN 和 COVID-19 肾损伤的新治疗方法
  • 批准号:
    10595512
  • 财政年份:
    2022
  • 资助金额:
    $ 39.38万
  • 项目类别:
A new therapeutic approach against kidney damage in LN and COVID-19
针对 LN 和 COVID-19 肾损伤的新治疗方法
  • 批准号:
    10389224
  • 财政年份:
    2022
  • 资助金额:
    $ 39.38万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了